Immutep Limited (IMMP)
NASDAQ: IMMP · Real-Time Price · USD
1.845
-0.115 (-5.88%)
Nov 21, 2024, 11:12 AM EST - Market open
Immutep Revenue
In the fiscal year ending June 30, 2024, Immutep had annual revenue of 3.84M AUD with 9.59% growth. Immutep had revenue of 1.73M in the half year ending June 30, 2024, a decrease of -34.22%.
Revenue (ttm)
3.84M AUD
Revenue Growth
+9.59%
P/S Ratio
n/a
Revenue / Employee
123,932 AUD
Employees
31
Market Cap
268.98M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 3.84M | 336.16K | 9.59% |
Jun 30, 2023 | 3.51M | -1.21M | -25.64% |
Jun 30, 2022 | 4.71M | 851.56K | 22.04% |
Jun 30, 2021 | 3.86M | -9.88M | -71.88% |
Jun 30, 2020 | 13.74M | 8.10M | 143.72% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
OraSure Technologies | 224.26M |
Vanda Pharmaceuticals | 190.86M |
Voyager Therapeutics | 163.78M |
Sage Therapeutics | 106.40M |
iTeos Therapeutics | 35.00M |
C4 Therapeutics | 33.67M |
uniQure | 28.59M |
Atai Life Sciences | 331.00K |
IMMP News
- 5 days ago - Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients - Seeking Alpha
- 7 days ago - Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial - Benzinga
- 7 days ago - Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer - GlobeNewsWire
- 23 days ago - Immutep Quarterly Activities Report Q1 FY25 - GlobeNewsWire
- 6 weeks ago - Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire
- 6 weeks ago - Immutep: Navigating The Bumps In The Road - Seeking Alpha
- 2 months ago - Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer - GlobeNewsWire
- 4 months ago - Immutep Quarterly Activities Report Q4 FY24 - GlobeNewsWire